<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.retrovirology.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Retrovirology - Latest Articles</title>
        <link>http://www.retrovirology.com</link>
        <description>The latest research articles published by Retrovirology</description>
        <dc:date>2012-02-10T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/14" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/13" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/12" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/11" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/10" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/9" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/8" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/7" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/6" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/5" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.retrovirology.com/content/9/1/14">
        <title>Insights into the structure and activity of the prototype foamy virus RNase H </title>
        <description>Background:
RNase H is an endonuclease that hydrolyzes the RNA strand in RNA/DNA hybrids. Retroviral reverse transcriptases harbor a C-terminal RNase H domain whose activity is essential for viral replication. The RNase H degrades the viral genomic RNA after the first DNA strand is synthesized. Here, we report the biophysical and enzymatic properties of the RNase H domain of prototype foamy virus (PFV) as an independently purified protein. Sequence comparisons with other retroviral RNases H indicated that PFV RNase H harbors a basic protrusion, including a basic loop and the so-called C-helix, which was suggested to be important for activity and substrate binding and is absent in the RNase H domain of human immunodeficiency virus. So far, no structure of a retroviral RNase H containing a C-helix is available.
Results:
RNase H activity assays demonstrate that the PFV RNase H domain is active, although its activity is about 200-fold reduced as compared to the full length protease-reverse transcriptase enzyme. Fluorescence equilibrium titrations with an RNA/DNA substrate revealed a KD for the RNase H domain in the low micromolar range which is about 4000-fold higher than that of the full-length protease-reverse transcriptase enzyme. Analysis of the RNase H cleavage pattern using a [32P]-labeled substrate indicates that the independent RNase H domain cleaves the substrate non-specifically.The purified RNase H domain exhibits a well defined three-dimensional structure in solution which is stabilized in the presence of Mg2+ ions.
Conclusions:
Our data demonstrate that the independent PFV RNase H domain is structured and active. The presence of the C-helix in PFV RNase H could be confirmed by assigning the protein backbone and calculating the chemical shift index using NMR spectroscopy.</description>
        <link>http://www.retrovirology.com/content/9/1/14</link>
                <dc:creator>Berit Leo</dc:creator>
                <dc:creator>Maximilian Hartl</dc:creator>
                <dc:creator>Kristian Schweimer</dc:creator>
                <dc:creator>Florian Mayr</dc:creator>
                <dc:creator>Birgitta Wohrl</dc:creator>
                <dc:source>Retrovirology 2012, null:14</dc:source>
        <dc:date>2012-02-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-14</dc:identifier>
                                    <dc:description>This paper demonstrates that the independent PFV RNase H domain is structured and active. The presence of the C-helix in PFV RNase H could be confirmed by assigning the protein backbone and calculating the chemical shift index using NMR spectroscopy.</dc:description>
                <prism:require>/content/figures/1742-4690-9-14-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>14</prism:startingPage>
        <prism:publicationDate>2012-02-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/13">
        <title>Spt6 levels are modulated by PAAF1 and proteasome to regulate the HIV-1 LTR </title>
        <description>Background:
Tat-mediated activation of the HIV-1 promoter depends upon a proteasome-associated factor, PAAF1, which dissociates 26S proteasome to produce 19S RP that is essential for transcriptional elongation. The effect of PAAF1 on proteasome activity could also potentially shield certain factors from proteolysis, which may be implicated in the transcriptional co-activator activity of PAAF1 towards the LTR.
Results:
Here, we show that Spt6 is targeted by proteasome in the absence of PAAF1. PAAF1 interacts with the N-terminus of Spt6, suggesting that PAAF1 protects Spt6 from proteolysis. Depletion of either PAAF1 or Spt6 reduced histone occupancy at the HIV-1 promoter, and induced the synthesis of aberrant transcripts. Ectopic Spt6 expression or treatment with proteasome inhibitor partially rescued the transcription defect associated with loss of PAAF1. Transcriptional profiling followed by ChIP identified a subset of cellular genes that are regulated in a similar fashion to HIV-1 by Spt6 and/or PAAF1, including many that are involved in cancer, such as BRCA1 and BARD1.
Conclusion:
These results show that intracellular levels of Spt6 are fine-tuned by PAAF1 and proteasome, which is required for HIV-1 transcription and extends to cellular genes implicated in cancer.</description>
        <link>http://www.retrovirology.com/content/9/1/13</link>
                <dc:creator>Mirai Nakamura</dc:creator>
                <dc:creator>Poornima Basavarajaiah</dc:creator>
                <dc:creator>Emilie Rousset</dc:creator>
                <dc:creator>Cyprien Beraud</dc:creator>
                <dc:creator>Daniel Latreille</dc:creator>
                <dc:creator>Imene-Sarah Henaoui</dc:creator>
                <dc:creator>Irina Lassot</dc:creator>
                <dc:creator>Bernard Mari</dc:creator>
                <dc:creator>Rosemary Kiernan</dc:creator>
                <dc:source>Retrovirology 2012, null:13</dc:source>
        <dc:date>2012-02-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-13</dc:identifier>
                                    <dc:description>This study shows that Spt6 is targeted by proteasome in the absence of PAAF1. PAAF1 interacts with the N-terminus of Spt6, suggesting that PAAF1 protects Spt6 from proteolysis.</dc:description>
                <prism:require>/content/figures/1742-4690-9-13-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>13</prism:startingPage>
        <prism:publicationDate>2012-02-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/12">
        <title>FIV establishes a latent infection in feline peripheral blood CD4+ T lymphocytes in vivo during the asymptomatic phase of infection</title>
        <description>Background:
Feline immunodeficiency virus (FIV) is a lentivirus of cats that establishes a lifelong persistent infection with immunologic impairment.
Results:
In an approximately 2 year-long experimental infection study, cats infected with a biological isolate of FIV clade C demonstrated undetectable plasma viral loads from 10 months post-infection onward.  Viral DNA was detected in CD4+CD25+ and CD4+CD25- T cells isolated from infected cats whereas viral RNA was not detected at multiple time points during the early chronic phase of infection.    Viral transcription could be reactivated in latently infected CD4+ T cells ex vivo as demonstrated by detectable FIV gag RNA and 2-long terminal repeat (LTR) circle junctions.  Viral LTR and gag sequences amplified from peripheral blood mononuclear cells during early and chronic stages of infection demonstrated minimal to no viral sequence variation.
Conclusions:
Collectively, these findings are consistent with FIV latency in peripheral blood CD4+ T cells isolated from chronically infected cats.  The ability to isolate latently FIV-infected CD4+ T lymphocytes from FIV-infected cats provides a platform for the study of in vivo mechanisms of lentiviral latency.</description>
        <link>http://www.retrovirology.com/content/9/1/12</link>
                <dc:creator>Brian Murphy</dc:creator>
                <dc:creator>Natasha Vapniarsky</dc:creator>
                <dc:creator>Chad Hillman</dc:creator>
                <dc:creator>Diego Castillo</dc:creator>
                <dc:creator>Samantha McDonnel</dc:creator>
                <dc:creator>Peter Moore</dc:creator>
                <dc:creator>Paul Luciw</dc:creator>
                <dc:creator>Ellen Sparger</dc:creator>
                <dc:source>Retrovirology 2012, null:12</dc:source>
        <dc:date>2012-02-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-12</dc:identifier>
                            <dc:title>FIV  latent infection in feline peripheral blood CD4+ T lymphocytes</dc:title>
                            <dc:description>This study shows that viral LTR and gag sequences amplified from peripheral blood mononuclear cells during early and chronic stages of infection demonstrated minimal to no viral sequence variation consistent with tight transcriptional latency in FIV infection in vivo.</dc:description>
                <prism:require>/content/figures/1742-4690-9-12-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2012-02-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/11">
        <title>Systemic inhibition of myeloid dendritic cells by circulating HLA class I molecules in HIV-1 infection
</title>
        <description>Background:
HIV-1 infection is associated with profound dysfunction of myeloid dendritic cells, for reasons that remain ill-defined. Soluble HLA class I molecules can have important inhibitory effects on T cells and NK cells, but may also contribute to reduced functional properties of professional antigen-presenting cells. Here, we investigated the expression of soluble HLA class I isoforms during HIV-1 infection and assessed their functional impact on antigen-presenting characteristics of dendritic cells.
Results:
Soluble HLA class I molecules were highly upregulated in progressive HIV-1 infection as determined by quantitative Western blots. This was associated with strong increases of intracellular expression of HLA class I isoforms in dendritic cells and monocytes. Using mixed lymphocyte reactions, we found that soluble HLA class I molecules effectively inhibited the antigen-presenting properties of dendritic cells, however, there was no significant influence of HLA class I molecules on the cytokine-secretion properties of these cells. The immunomodulatory effects of soluble HLA class I molecules were mediated by interactions with inhibitory myelomonocytic MHC class I receptors from the Leukocyte Immunoglobulin Like Receptor (LILR) family.
Conclusions:
During progressive HIV-1 infection, soluble HLA class I molecules can contribute to systemic immune dysfunction by inhibiting the antigen-presenting properties of myeloid dendritic cells through interactions with inhibitory myelomonocytic HLA class I receptors.</description>
        <link>http://www.retrovirology.com/content/9/1/11</link>
                <dc:creator>Jinghe Huang</dc:creator>
                <dc:creator>Maha Al-Mozaini</dc:creator>
                <dc:creator>Jerome Rogich</dc:creator>
                <dc:creator>Mary Carrington</dc:creator>
                <dc:creator>Katherine Seiss</dc:creator>
                <dc:creator>Florencia Pereyra</dc:creator>
                <dc:creator>Mathias Lichterfeld</dc:creator>
                <dc:creator>Xu Yu</dc:creator>
                <dc:source>Retrovirology 2012, null:11</dc:source>
        <dc:date>2012-01-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-11</dc:identifier>
                                    <dc:description>During progressive HIV-1 infection, soluble HLA class I molecules can contribute to systemic immune dysfunction by inhibiting the antigen-presenting properties of myeloid dendritic cells through interactions with inhibitory myelomonocytic HLA class I receptors.</dc:description>
                <prism:require>/content/figures/1742-4690-9-11-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2012-01-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/10">
        <title>Bone marrow stromal cell antigen 2 (BST-2) restricts mouse mammary tumor virus (MMTV) replication in vivo</title>
        <description>Background:
Bone marrow stromal cell antigen 2 (BST-2) is a cellular factor that restricts the egress of viruses such as human immunodeficiency virus (HIV-1) from the surface of infected cells, preventing infection of new cells. BST-2 is variably expressed in most cell types and its expression is enhanced by cytokines such as type I interferon alpha (IFN-alpha). In this present study, we used the beta-retrovirus, mouse mammary tumor virus (MMTV) as a model to examine the role of mouse BST-2 in host infection in vivo.
Results:
By using RNA interference, we show that loss of BST-2 enhances MMTV replication in cultured mammary tumor cells and in vivo. In cultured cells, BST-2 inhibits virus accumulation in the culture medium, and co-localizes at the cell surface with virus structural proteins.   Furthermore, both scanning electron micrograph (SEM) and Transmission electron micrograph (TEM) show that MMTV accumulates on the surface of IFN alpha-stimulated cells.
Conclusions:
Our data provide evidence that BST-2 restricts MMTV release from naturally infected cells and that BST-2 is an antiviral factor in vivo.Running Title:  BST-2 restriction of virus replication in vivoKeywordsBST-2, Tetherin, Interferon alpha, MMTV, In vivo, SEM, TEM</description>
        <link>http://www.retrovirology.com/content/9/1/10</link>
                <dc:creator>Philip Jones</dc:creator>
                <dc:creator>Harshini Mehta</dc:creator>
                <dc:creator>Martina Maric</dc:creator>
                <dc:creator>Richard Roller</dc:creator>
                <dc:creator>Chioma Okeoma</dc:creator>
                <dc:source>Retrovirology 2012, null:10</dc:source>
        <dc:date>2012-01-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-10</dc:identifier>
                                    <dc:description>The findings in this work show that BST-2 restricts MMTV release from naturally infected cells and that BST-2 is an antiviral factor in vivo.</dc:description>
                <prism:require>/content/figures/1742-4690-9-10-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2012-01-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/9">
        <title>The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodies</title>
        <description>Background:
The conserved CD4 binding site (CD4bs) on HIV-1 gp120 is a major target for vaccines. It is a priority to determine sites and structures within the CD4bs that are important for inclusion in vaccines. We studied a gp120 pocket penetrated by W100 of the potent CD4bs monoclonal antibody (mab), b12. We compared HIV-1 envelopes and corresponding mutants that carried blocked W100 pockets to evaluate whether other CD4bs mabs target this site.FindingsAll CD4bs mabs tested blocked soluble CD4 binding to gp120 consistent with their designation as CD4bs directed antibodies. All CD4bs mabs tested neutralized pseudovirions carrying NL4.3 wt envelope. However, only b12 failed to neutralize pseudoviruses carrying mutant envelopes with a blocked W100 pocket. In addition, for CD4bs mabs that neutralized pseudovirions carrying primary envelopes, mutation of the W100 pocket had little or no effect on neutralization sensitivity.
Conclusions:
Our data indicate that the b12 W100 pocket on gp120 is infrequently targeted by CD4bs mabs. This site is therefore not a priority for preservation in vaccines aiming to elicit antibodies targeting the CD4bs.</description>
        <link>http://www.retrovirology.com/content/9/1/9</link>
                <dc:creator>Maria Duenas-Decamp</dc:creator>
                <dc:creator>Olivia O'Connell</dc:creator>
                <dc:creator>Davide Corti</dc:creator>
                <dc:creator>Susan Zolla-Pazner</dc:creator>
                <dc:creator>Paul Clapham</dc:creator>
                <dc:source>Retrovirology 2012, null:9</dc:source>
        <dc:date>2012-01-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-9</dc:identifier>
                                    <dc:description>This study indicates that the b12 W100 pocket on gp120 is targeted infrequently by CD4bs mabs. This site is therefore not a priority for preservation in vaccines aiming to elicit antibodies targeting the CD4bs.</dc:description>
                <prism:require>/content/figures/1742-4690-9-9-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2012-01-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/8">
        <title>Translation of MMTV Gag requires nuclear events involving splicing motifs in addition to the viral Rem protein and RmRE</title>
        <description>Background:
Retroviral Gag proteins are encoded in introns, and because of this localization, they are subject to the default pathways of pre-mRNA splicing. Retroviruses regulate splicing and translation through a variety of intertwined mechanisms, including 5&apos;- post-transcriptional control elements, 3&apos;- constitutive transport elements, and viral protein RNA interactions that couple unspliced and singly spliced mRNAs to transport machinery. Sequences within the gag gene termed inhibitory or instability sequences also appear to affect message stability and translation, and the action of these sequences can be countered by silent mutation or the presence of RNA interaction proteins like HIV-1 Rev. Here, we explored the requirements for mouse mammary tumor virus (MMTV) Gag expression using a combination of in vivo and in vitro expression systems.
Results:
We show that MMTV gag alleles are inhibited for translation despite possessing a functional open reading frame (ORF). The block to expression was post-transcriptional and targeted the mRNA but was not a function of mRNA transport or stability. Using bicistronic reporters, we show that inhibition of gag expression imparted a block to both cap-dependent and cap-independent translation onto the message. Direct introduction of in vitro synthesized gag mRNA resulted in translation, implying a nuclear role in inhibition of expression. The inhibition of expression was overcome by intact proviral expression or by flanking gag with splice sites combined with a functional Rem-Rem response element (RmRE) interaction.
Conclusions:
Expression of MMTV Gag requires nuclear interactions involving the viral Rem protein, its cognate binding target the RmRE, and surprisingly, both a splice donor and acceptor sequence to achieve appropriate signals for translation of the mRNA in the cytoplasm.</description>
        <link>http://www.retrovirology.com/content/9/1/8</link>
                <dc:creator>Ioana Boeras</dc:creator>
                <dc:creator>Michael Sakalian</dc:creator>
                <dc:creator>John West</dc:creator>
                <dc:source>Retrovirology 2012, null:8</dc:source>
        <dc:date>2012-01-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-8</dc:identifier>
                            <dc:title>Nuclear experience of Gag mRNA influences its translation</dc:title>
                            <dc:description>This paper shows that the translation of MMTV Gag mRNA is negatively regulated by a nuclear &quot;experience&quot; and that viral Rem protein, viral RmRE sequence,and a splice donor and acceptor are needed to counter the negative translational effect on Gag mRNA in the cytoplasm.</dc:description>
                <prism:require>/content/figures/1742-4690-9-8-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2012-01-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/7">
        <title>Human immunodeficiency virus type 1 envelope proteins traffic toward virion assembly sites via a TBC1D20/Rab1-regulated pathway</title>
        <description>Background:
The cellular activity of many factors and pathways is required to execute the complex replication cycle of the human immunodeficiency virus type 1 (HIV-1). To reveal these cellular components, several extensive RNAi screens have been performed, listing numerous &apos;HIV-dependency factors&apos;. However, only a small overlap between these lists exists, calling for further evaluation of the relevance of specific factors to HIV-1 replication and for the identification of additional cellular candidates. TBC1D20, the GTPase-activating protein (GAP) of Rab1, regulates endoplasmic reticulum (ER) to Golgi trafficking, was not identified in any of these screens, and its involvement in HIV-1 replication cycle is tested here.FindingsExcessive TBC1D20 activity perturbs the early trafficking of HIV-1 envelope protein through the secretory pathway. Overexpression of TBC1D20 hampered envelope processing and reduced its association with detergent-resistant membranes, entailing a reduction in infectivity of HIV-1 virion like particles (VLPs).
Conclusions:
These findings add TBC1D20 to the network of host factors regulating HIV replication cycle.</description>
        <link>http://www.retrovirology.com/content/9/1/7</link>
                <dc:creator>Dikla Nachmias</dc:creator>
                <dc:creator>Ella Sklan</dc:creator>
                <dc:creator>Marcelo Ehrlich</dc:creator>
                <dc:creator>Eran Bacharach</dc:creator>
                <dc:source>Retrovirology 2012, null:7</dc:source>
        <dc:date>2012-01-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-7</dc:identifier>
                                    <dc:description>Excessive TBC1D20 activity perturbs the early trafficking of HIV-1 envelope protein through the secretory pathway. Overexpression of TBC1D20 hampered envelope processing and reduced its association with detergent-resistant membranes, entailing a reduction in infectivity of HIV-1 virion like particles (VLPs).</dc:description>
                <prism:require>/content/figures/1742-4690-9-7-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2012-01-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/6">
        <title>HIV infection and HERV expression: a review</title>
        <description>The human genome contains multiple copies of retrovirus genomes known as endogenous retroviruses (ERVs) that have entered the germ-line at some point in evolution. Several of these proviruses have retained (partial) coding capacity, so that a number of viral proteins or even virus particles are expressed under various conditions. Human ERVs (HERVs) belong to the beta-, gamma-, or spuma- retrovirus groups. Endogenous delta- and lenti- viruses are notably absent in humans, although endogenous lentivirus genomes have been found in lower primates. Exogenous retroviruses that currently form a health threat to humans intriguingly belong to those absent groups. The best studied of the two infectious human retroviruses is the lentivirus human immunodeficiency virus (HIV) which has an overwhelming influence on its host by infecting cells of the immune system. One HIV-induced change is the induction of HERV transcription, often leading to induced HERV protein expression. This review will discuss the potential HIV-HERV interactions.Several studies have suggested that HERV proteins are unlikely to complement defective HIV virions, nor is HIV able to package HERV transcripts, probably due to low levels of sequence similarity. It is unclear whether the expression of HERVs has a negative, neutral, or positive influence on HIV-AIDS disease progression. A positive effect was recently reported by the specific expression of HERVs in chronically HIV-infected patients, which results in the presentation of HERV-derived peptides to CD8+ T-cells. These cytotoxic T-cells were not tolerant to HERV peptides, as would be expected for self-antigens, and consequently lysed the HIV-infected, HERV-presenting cells. This novel mechanism could control HIV replication and result in a low plasma viral load. The possibility of developing a vaccination strategy based on these HERV peptides will be discussed.</description>
        <link>http://www.retrovirology.com/content/9/1/6</link>
                <dc:creator>Antoinette van der Kuyl</dc:creator>
                <dc:source>Retrovirology 2012, null:6</dc:source>
        <dc:date>2012-01-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-6</dc:identifier>
                                    <dc:description>The human genome contains multiple copies of retrovirus genomes known as endogenous retroviruses (ERVs) that have entered the germ-line at some point in evolution. This review discusses how HIV-1 infection influences the expression of HERVs.</dc:description>
                <prism:require>/content/figures/1742-4690-9-6-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2012-01-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/5">
        <title>Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients</title>
        <description>Background:
HIV-1-infected elite controllers or suppressors (ES) maintain undetectable viral loads (&lt;50 copies/mL) without antiretroviral therapy. The mechanisms of suppression are incompletely understood. Modulation of HIV-1 replication by miRNAs has been reported, but the role of small RNAs in ES is unknown. Using samples from a well-characterized ES cohort, untreated viremic patients, and uninfected controls, we explored the PBMC miRNA profile and probed the relationships of miRNA expression, CD4+ T-cell counts, and viral load.
Results:
miRNA profiles, obtained using multiple acquisition, data processing, and analysis methods, distinguished ES and uninfected controls from viremic HIV-1-infected patients. For several miRNAs, however, ES and viremic patients shared similar expression patterns. Differentially expressed miRNAs included those with reported roles in HIV-1 latency (miR-29 family members, miRs -125b and -150). Others, such as miR-31 and miR-31*, had no previously reported connection with HIV-1 infection but were found here to differ significantly with uncontrolled HIV-1 replication. Correlations of miRNA expression with CD4+ T-cell count and viral load were found, and we observed that ES with low CD4+ T-cell counts had miRNA profiles more closely related to viremic patients than controls. However, expression patterns indicate that miRNA variability cannot be explained solely by CD4 variation.
Conclusions:
The intimate involvement of miRNAs in disease processes is underscored by connections of miRNA expression with the HIV disease clinical parameters of CD4 count and plasma viral load. However, miRNA profile changes are not explained completely by these variables. Significant declines of miRs-125b and -150, among others, in both ES and viremic patients indicate the persistence of host miRNA responses or ongoing effects of infection despite viral suppression by ES. We found no negative correlations with viral load in viremic patients, not even those that have been reported to silence HIV-1 in vitro, suggesting that the effects of these miRNAs are exerted in a focused, cell-type-specific manner. Finally, the observation that some ES with low CD4 counts were consistently related to viremic patients suggests that miRNAs may serve as biomarkers for risk of disease progression even in the presence of viral suppression.</description>
        <link>http://www.retrovirology.com/content/9/1/5</link>
                <dc:creator>Kenneth Witwer</dc:creator>
                <dc:creator>Andria Watson</dc:creator>
                <dc:creator>Joel Blankson</dc:creator>
                <dc:creator>Janice Clements</dc:creator>
                <dc:source>Retrovirology 2012, null:5</dc:source>
        <dc:date>2012-01-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-5</dc:identifier>
                            <dc:title>MicroRNA plays key role in HIV suppression</dc:title>
                            <dc:description>miRNA profiles, obtained using multiple acquisition, data processing, and analysis methods, distinguished ES and uninfected controls from viremic HIV-1-infected patients. For several miRNAs, however, ES and viremic patients shared similar expression patterns. Differentially expressed miRNAs included those with reported roles in HIV-1 latency (miR-29 family members, miRs -125b and -150). Others, such as miR-31 and miR-31*, had no previously reported connection with HIV-1 infection but were found here to differ significantly with uncontrolled HIV-1 replication.</dc:description>
                <prism:require>/content/figures/1742-4690-9-5-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2012-01-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

